SentiBioLogo.jpg
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
27 janv. 2023 08h00 HE | Senti Biosciences, Inc.
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other...
SentiBioLogo.jpg
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
19 déc. 2022 07h55 HE | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
SentiBioLogo.jpg
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
11 déc. 2022 09h00 HE | Senti Biosciences, Inc.
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is...
SentiBioLogo.jpg
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
23 nov. 2022 07h55 HE | Senti Biosciences, Inc.
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and...
SentiBioLogo.jpg
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
10 nov. 2022 07h55 HE | Senti Biosciences, Inc.
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
SentiBioLogo.jpg
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
20 sept. 2022 16h02 HE | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
SentiBioLogo.jpg
Senti Bio Reports Second Quarter Financial Results and Business Updates
15 août 2022 16h05 HE | Senti Biosciences, Inc.
- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - ...
SentiBioLogo.jpg
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
09 juin 2022 07h30 HE | Senti Biosciences, Inc.
- Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti...
Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer
25 mai 2022 08h30 HE | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as...
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
24 mai 2022 08h30 HE | Senti Biosciences, Inc.
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business...